Christian Jede

Dr. Christian Jede

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
AHAndre Hermans
Andre Hermans
JMJohanna Milsmann
Johanna Milsmann
HLHanlin Li
Hanlin Li
CJChristian Jede
Christian Jede
AMAndrea Moir
Andrea Moir
MCMichael Cohen
Michael Cohen
This manuscript represents the view of the Dissolution Working Group of the IQ Consortium on the challenges of and recommendations on solubility measurements and development of dissolution methods for immediate release (IR) solid oral dosage forms formulated with amorphous solid dispersions. Nowadays, numerous compounds populate the industrial pipeline as promising drug candidates yet suffer from low aqueous solubility. In the oral drug product development process, solubility along with permeability is a key determinant to assure sufficient drug absorption along the intestinal tract. Formulating the drug candidate as an amorphous solid dispersion (ASD) is one potential option to address this issue. These formulations demonstrate the rapid onset of drug dissolution and can achieve supersaturated concentrations, which poses significant challenges to appropriately characterize solubility and develop quality control dissolution methods. This review strives to categorize the different dissolution and solubility challenges for ASD associated with 3 different topics: (i) definition of solubility and sink conditions for ASD dissolution, (ii) applications and development of non-sink dissolution (according to conventional definition) for ASD formulation screening and QC method development, and (iii) the advantages and disadvantages of using dissolution in detecting crystallinity in ASD formulations. Related to these challenges, successful examples of dissolution experiments in the context of control strategies are shared and may lead as an example for scientific consensus concerning dissolution testing of ASD.

1 February 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CJChristian Jede
Christian Jede
CWChristian Wagner
Christian Wagner
HKHolger Kubas
Holger Kubas
CWChristian Weber
Christian Weber
MWMarkus Weigandt
Markus Weigandt
Werner WeitschiesWerner Weitschies
Werner Weitschies

26 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CJChristian Jede
Christian Jede
LHLaura J. Henze
Laura J. Henze
KMKirstin Meiners
Kirstin Meiners
MBMalte Bogdahn
Malte Bogdahn
MWMarcel Wedel
Marcel Wedel
VAValeria van Axel
Valeria van Axel
A variety of in vitro dissolution and gastrointestinal transfer models have been developed aiming to predict drug supersaturation and precipitation. Further, biphasic, one-vessel in vitro systems are increasingly applied to simulate drug absorption in vitro. However, to date, there is a lack of combining the two approaches. Therefore, the first aim of this study was to develop a dissolution-transfer-partitioning system (DTPS) and, secondly, to assess its biopredictive power. In the DTPS, simulated gastric and intestinal dissolution vessels are connected via a peristaltic pump. An organic layer is added on top of the intestinal phase, serving as an absorptive compartment. The predictive power of the novel DTPS was assessed to a classical USP II transfer model using a BCS class II weak base with poor aqueous solubility, MSC-A. The classical USP II transfer model overestimated simulated intestinal drug precipitation, especially at higher doses. By applying the DTPS, a clearly improved estimation of drug supersaturation and precipitation and an accurate prediction of the in vivo dose linearity of MSC-A were observed. The DTPS provides a useful tool taking both dissolution and absorption into account. This advanced in vitro tool offers the advantage of streamlining the development process of challenging compounds.

29 August 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
HKHannah S. Kirschbaum
Hannah S. Kirschbaum
NKNiklas J. Koehl
Niklas J. Koehl
JBJohannes A. Blechar
Johannes A. Blechar
CWChristina Wiesinger
Christina Wiesinger
LKLaura J. Koehl
Laura J. Koehl
BGBrendan Griffin
Brendan Griffin
The pH stat in vitro lipolysis method is well established for evaluating lipid-based formulations (LBFs), however the absence of a simulated gastrointestinal transition may lead to an overestimation of drug precipitation particularly in the case of weakly basic drugs. This study aimed to compare the conventional pH-stat method with a pH-shift lipolysis approach by evaluating a diverse set of LBFs using nilotinib, a weakly basic model drug. Additionally, the study sought to assess in vitro-in vivo relationships (IVIVRs) and enhance understanding of the predictive capabilities of these models. Four nilotinib-containing LBFs were tested in vitro, and pharmacokinetic profiles were evaluated in Sprague Dawley rats. The formulations included a supersaturated Peceol® solution (sLBF), a Peceol® lipid suspension (type I according to the Lipid Formulation Classification System (LFCS)), a type III LFCS medium-chain suspension, and a type IV LFCS suspension. The highest bioavailability was achieved with the Peceol® sLBF and the type III LFCS formulation. Strong IVIVRs were established for both in vitro lipolysis models. In conclusion, utilizing both in vitro models offered distinct advantages depending on the stage of development and the specific questions being addressed. This approach contributes to more efficient formulation development and a reduced reliance on animal studies in early-stage drug development.

1 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HKHannah Sofie Kirschbaum
Hannah Sofie Kirschbaum
CJChristian Jede
Christian Jede
LKLaura J. Koehl
Laura J. Koehl
MKMartin Kuentz
Martin Kuentz
René HolmRené Holm
René Holm
POPatrick J. Odwyer
Patrick J. Odwyer
Lipid-based‑formulations (LBFs) are widely used to improve oral bioavailability of poorly water‑soluble drugs. Despite their widespread use in predicting formulation performance, standard in vitro lipolysis assays often lack an absorptive sink and fail to capture the transition from gastric to intestinal environments, thereby reducing their predictive relevance for in vivo outcomes. The aim of this study was to develop a biphasic in vitro lipolysis model incorporating an absorptive sink. In this model, the absorptive sink was provided by a decanol layer, and to simulate gastrointestinal transit, two dynamic pH‑transition approaches were employed: a biphasic GI‑transfer model and a biphasic pH‑shift model. Using nilotinib‑loaded LBFs, the study established conditions for this biphasic system and examined how media composition and lipase source influence drug concentrations during formulation dispersion, digestion, and partitioning into the organic sink. The results showed that digestion experiments conducted with either porcine pancreatin or Palatase® 20000 L increased the concentration of nilotinib in the aqueous digestion medium, which correspondingly reduced partitioning of the drug into the decanol layer. For the readily dispersible Type III LBF in the biphasic GI‑transfer setup, nilotinib permeation into the decanol layer decreased compared with a lipid‑free control, likely due to improved drug solubilization in the aqueous digestion phase. In contrast, the poorly dispersible Type I LBF was better suited to the biphasic pH‑shift setup, but it showed higher drug levels in the decanol layer, reflecting rapid partitioning of lipids—and associated crystalline drug—into the organic phase. Overall, this study establishes suitable conditions for evaluating the lipolysis of LBFs during a dynamic pH transition in the presence of an absorptive sink. This advanced approach provides additional insight to explore digestion‑mediated and/or pH‑mediated supersaturation during digestion of LBFs.